Predictors of recurrence and patterns of failure among patients treated with nephroureterectomy for upper tract urothelial carcinoma

Ryan T. Hughes , John T. Lucas , Louis Spencer Krane , Jude L. Divers , Ashok K. Hemal , Bart A. Frizzell
{"title":"Predictors of recurrence and patterns of failure among patients treated with nephroureterectomy for upper tract urothelial carcinoma","authors":"Ryan T. Hughes ,&nbsp;John T. Lucas ,&nbsp;Louis Spencer Krane ,&nbsp;Jude L. Divers ,&nbsp;Ashok K. Hemal ,&nbsp;Bart A. Frizzell","doi":"10.1016/j.ctrc.2015.12.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Recurrence rates following nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) remain high. As such, adjuvant therapy directed at high risk sites may improve long term outcomes. We describe patterns and predictors of UTUC recurrence according to patient, disease and treatment-related factors.</p></div><div><h3>Methods and materials</h3><p>We reviewed the records of 113 patients treated with NU for UTUC at our institution between 2006 and 2013. Time to locoregional (LR), intravesical (IV), distant recurrence and death were described using the Kaplan–Meier method and compared using the log rank statistic. Cox Proportional Hazards analyses were performed to evaluate the adjusted hazard for LR/IV and LR recurrence.</p></div><div><h3>Results</h3><p>Advanced T stage (T3/4) was present in 41 (36%) patients, 10 (9%) were node-positive and 21 (19%) showed evidence of lymphovascular space invasion (LVSI). Median overall survival and time to any recurrence was 54.6 and 20.7 months, respectively. Disease recurrence was observed in 48 (42%) patients. The location of failure was intravesical in 27 (24%), locoregional in 22 (19%) and distant in 20 (18%). Three-year LR/IV and distant failure rates were 38.7% and 22.2%, respectively. Three-year LR failure was 4.6% in pTa-2 vs. 25.8% in T3–T4 disease. Multivariate analysis identified history of prior bladder disease as a significant predictor of LR/IV recurrence.</p></div><div><h3>Conclusions</h3><p>In this study we demonstrate LR/IV recurrence as the predominant pattern of failure in UTUC patients treated with nephroureterectomy. This systematic description of recurrence patterns and associated factors will guide further investigation of adjuvant therapy to minimize the treatment failures defined herein.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.12.004","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213089615300372","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Recurrence rates following nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) remain high. As such, adjuvant therapy directed at high risk sites may improve long term outcomes. We describe patterns and predictors of UTUC recurrence according to patient, disease and treatment-related factors.

Methods and materials

We reviewed the records of 113 patients treated with NU for UTUC at our institution between 2006 and 2013. Time to locoregional (LR), intravesical (IV), distant recurrence and death were described using the Kaplan–Meier method and compared using the log rank statistic. Cox Proportional Hazards analyses were performed to evaluate the adjusted hazard for LR/IV and LR recurrence.

Results

Advanced T stage (T3/4) was present in 41 (36%) patients, 10 (9%) were node-positive and 21 (19%) showed evidence of lymphovascular space invasion (LVSI). Median overall survival and time to any recurrence was 54.6 and 20.7 months, respectively. Disease recurrence was observed in 48 (42%) patients. The location of failure was intravesical in 27 (24%), locoregional in 22 (19%) and distant in 20 (18%). Three-year LR/IV and distant failure rates were 38.7% and 22.2%, respectively. Three-year LR failure was 4.6% in pTa-2 vs. 25.8% in T3–T4 disease. Multivariate analysis identified history of prior bladder disease as a significant predictor of LR/IV recurrence.

Conclusions

In this study we demonstrate LR/IV recurrence as the predominant pattern of failure in UTUC patients treated with nephroureterectomy. This systematic description of recurrence patterns and associated factors will guide further investigation of adjuvant therapy to minimize the treatment failures defined herein.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾输尿管切除术治疗上尿路上皮癌患者复发和失败的预测因素
目的肾输尿管切除术(NU)治疗上尿路上皮癌(UTUC)后的复发率仍然很高。因此,针对高风险部位的辅助治疗可能会改善长期预后。我们根据患者、疾病和治疗相关因素描述UTUC复发的模式和预测因素。方法和材料我们回顾了2006年至2013年我院113例使用NU治疗UTUC的患者的记录。使用Kaplan-Meier方法描述局部时间(LR)、膀胱内时间(IV)、远处复发和死亡,并使用对数秩统计进行比较。采用Cox比例风险分析来评估LR/IV和LR复发的校正风险。结果晚期T期(T3/4) 41例(36%),淋巴结阳性10例(9%),淋巴血管间隙浸润(LVSI) 21例(19%)。中位总生存期和复发时间分别为54.6个月和20.7个月。48例(42%)患者出现疾病复发。失败部位为膀胱内27例(24%),局部22例(19%),远处20例(18%)。3年LR/IV和远期失败率分别为38.7%和22.2%。pTa-2患者3年LR失败率为4.6%,T3-T4患者为25.8%。多因素分析表明,既往膀胱疾病史是LR/IV复发的重要预测因素。结论在本研究中,我们证明了LR/IV复发是UTUC患者行肾输尿管切除术失败的主要模式。对复发模式和相关因素的系统描述将指导辅助治疗的进一步研究,以尽量减少本文所定义的治疗失败。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: A case report Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study Multiple nodular lung metastases with no obvious primary showing low positive 18-fluoro deoxyglucose (FDG) uptake on positron emission tomography (PET) scan: A unique case of metastatic ameloblastoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1